Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Overview | 8 | 1 |
| Therapeutics Development | 9 | 3 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Products under Development by Stage of Development | 9 | 1 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Products under Development by Therapy Area | 10 | 1 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Products under Development by Indication | 11 | 1 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Products under Development by Companies | 14 | 2 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Products under Development by Universities/Institutes | 16 | 2 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Therapeutics Assessment | 18 | 7 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 2 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 2 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Companies Involved in Therapeutics Development | 25 | 7 |
| Biotest AG | 25 | 1 |
| CEL-SCI Corporation | 26 | 1 |
| Fountain Biopharma Inc. | 27 | 1 |
| Immupharma Plc | 28 | 1 |
| Inovio Pharmaceuticals, Inc. | 29 | 1 |
| TaiMed Biologics Inc. | 30 | 1 |
| United Biomedical, Inc. | 31 | 1 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Drug Profiles | 32 | 28 |
| 3BNC-117 Drug Profile | 32 | 2 |
| CEL-1000 Drug Profile | 34 | 2 |
| forigerimod acetate Drug Profile | 36 | 3 |
| HIV vaccine 2 Drug Profile | 39 | 1 |
| ibalizumab Drug Profile | 40 | 2 |
| ibalizumab biosimilar Drug Profile | 42 | 1 |
| ibalizumab second generation Drug Profile | 43 | 1 |
| M-48U1 Drug Profile | 44 | 1 |
| MAX-16H5 Drug Profile | 45 | 1 |
| Monoclonal Antibodies to Target CD4 and CD8 for Type 1 Diabetes Drug Profile | 46 | 1 |
| Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 Drug Profile | 47 | 1 |
| Monoclonal Antibody to Inhibit CD4 for HIV Drug Profile | 48 | 1 |
| Small Molecules to Activate CD4 for HIV Drug Profile | 49 | 1 |
| Small Molecules to Inhibit CD4 and MHC Class I for HIV Drug Profile | 50 | 1 |
| Small Molecules to Target CD4 for HIV Drug Profile | 51 | 1 |
| TMB-360 Drug Profile | 52 | 1 |
| tregalizumab Drug Profile | 53 | 3 |
| UB-421 Drug Profile | 56 | 1 |
| VRC-01 Drug Profile | 57 | 3 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Dormant Projects | 60 | 4 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Discontinued Products | 64 | 1 |
| T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Featured News &Press Releases | 65 | 10 |
| Jun 07, 2016: First European Patients Commence Dosing In Lupuzor's Pivotal Phase III Study | 65 | 1 |
| May 24, 2016: Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial | 65 | 1 |
| May 06, 2016: Antibody therapy opens door to potential new treatment for HIV | 66 | 1 |
| May 05, 2016: Broadly neutralizing antibodies improve immune response; clear HIV reservoirs | 67 | 1 |
| Apr 27, 2016: Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial | 68 | 1 |
| Apr 27, 2016: Single Antibody Infusions Provide Durable Protection Against HIV-Like Virus in Monkeys | 68 | 1 |
| Mar 09, 2016: First European site opened in France and patient recruitment commences in Lupuzor pivotal phase III study | 69 | 1 |
| Feb 15, 2016: First US Patients Commence Dosing In Lupuzor Pivotal Phase III Study | 70 | 1 |
| Dec 15, 2015: Over 70 Lupus Specialists Gather in Paris for Lupuzor s Phase III Investigators Meeting | 70 | 1 |
| Dec 07, 2015: Lupuzor Pivotal Phase III Trial Recruiting First US Lupus Patients | 71 | 1 |
| Nov 09, 2015: Biotest to present data from TREAT 2b trial at The American College of Rheumatology 2015 Annual Meeting | 71 | 1 |
| Nov 04, 2015: ImmuPharma Provides Lupuzor Phase III Pivotal Trial Update | 72 | 1 |
| Jul 27, 2015: Clinicaltrials.Gov Registration Of Lupuzor Pivotal Phase III Trial | 73 | 1 |
| Jun 25, 2015: Lupuzor's Founder, Dr Slyviane Muller - Awarded Medal of Innovation from CNRS for Lupuzor | 73 | 1 |
| Apr 24, 2015: Biotest AG: Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million | 74 | 1 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |